NextCure, Inc. (NXTC)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in NextCure, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

NextCure, Inc. (NXTC) has returned -24.74% so far this year and 85.30% over the past 12 months.

Based on dividend-adjusted daily data since May 9, 2019, NXTC's average daily return is +0.03%, while the average monthly return is -0.90%.

Historically, 40% of months were positive and 60% were negative. The best month was Oct 2025 with a return of +115.0%, while the worst month was Jul 2020 at -58.4%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 7 months.

On a daily basis, NXTC closed higher 46% of trading days. The best single day was Nov 5, 2019 with a return of +248.9%, while the worst single day was Jul 13, 2020 at -54.4%.

NextCure, Inc. has an annualized alpha of -4.50%, beta of 0.87, and R² of 0.02 versus S&P 500 Index. Calculated based on daily prices since May 10, 2019.

• This stock participated in 183.89% of S&P 500 Index downside but only 0.28% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.02 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

NXTC ranks 71 for risk / return — better than 71% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for NextCure, Inc. (NXTC) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the NextCure, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the NextCure, Inc. was 99.71%, occurring on Apr 10, 2025. The portfolio has not yet recovered.

The current NextCure, Inc. drawdown is 99.03%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of NextCure, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how NextCure, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.